Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Immune Thrombocytopenia
- Main trialPhase 1
- “The goal of this clinical trial is to demonstrate GL-2045 safety and efficacy proof of concept by demonstrating intravenous immunoglobulin (IVig)-like platelet responses in adult patients with Immune Thrombocytopenia (ITP).”In the company’s words, NCT07605845 on ClinicalTrials.gov
Other drugs for Immune Thrombocytopenia
- RilzabrutinibSanofi · Phase 3
- Human immunoglobulinGrand Shuyang Life Sciences (Chengdu) Co., Ltd. · Phase 3
- Kedrion IVIG 10%Kedrion S.p.A. · Phase 3
- TQB3473Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase 3
- Efgartigimodargenx · Phase 3
- QL0911Qilu Pharmaceutical · Phase 3
Coming up1
- 6 Dec 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 6 Dec 2027 | Safety and Efficacy of GL-2045 in Patients With Immune Thrombocytopenia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026